

IN THE CLAIMS

1. (Original) A pharmaceutical anti-herpetic composition comprising a virion vaccine anti-herpetic preparation containing herpes simplex viruses of serotypes 1 or 2 inactivated by formalin or γ -radiation, and an immunocompetent substance, characterized in that it contains Polyoxidonium, valine, lysine, and a combination consisting of at least two metabolic amino acids selected from the group: phenylalanine, leucine, alanine, threonine, histidine, arginine, methionine, with the following proportion of the components:

anti-herpetic preparation - 10^6 to 10^7 plaque-forming units/ml of suspension	
Polyoxidonium	0.03-0.06 g
valine	0.18-0.25 g
lysine	0.15-0.30 g
combination of metabolic amino acids	0.12- 0.27 g
physiological liquid medium	to 100 ml

2. (Original) The composition according to claim 1, characterized in that it further comprises an amino acid isoleucine in an amount of 0.11-0.22 g per 100 ml of the composition.

3. (Original) The composition according to claim 2, characterized in that it further comprises human albumin in an amount of 0.22-0.24 g per 100 ml.

4. (Original) The composition according to claim 3, characterized in that it further comprises one or more water- and fat-soluble vitamins selected from the group: thiamine, riboflavin, nicotine amide, pyridoxine, ascorbic acid, retinol, tocopherol, or their mixtures in the formulation of the composition in the total amount of from 0.05 to 3.5%.

5. (Original) The composition according to claim 4, characterized in that it can be formulated into a dosage form in which a solid, soft or liquid substance can be used as a carrier.
6. (Original) The composition according to claim 5, characterized in that with the use of a solid carrier the final form is a tablet, dragee, granule, sachet or powder placed into a capsule.
7. (Original) The composition according to claim 5, characterized in that with the use of a liquid carrier the end product is a solution, gel, emulsion, suspension, mixture, syrup or liniment.
8. (Original) The composition according to claim 5, characterized in that with the use of a soft carrier the end product is an ointment, crème, paste, suppository, implant or chewing tablet, or pastille.
9. (Currently Amended) A method for preparing a suppository based on the pharmaceutical composition characterized in ~~claims~~ claim 1 [[-4]], which method comprises mixing, by following a conventional technology, of the active components and cocoa oil as a carrier, characterized in that the composition characterized in ~~claims 1-4~~ and one or more microelements (MEs) selected from the group: zinc, chromium, selenium and nickel are introduced as the active components.
10. (Original) The method according to claim 9, characterized in that the MEs are introduced as soluble chelate forms in an amount of 0.01-0.08% based on the total weight of the composition.
11. (Currently Amended) A method for use of the pharmaceutical anti-herpetic

composition by administering it to an organism affected by herpes virus, characterized in that the composition characterized in ~~claims~~ claim 1 [[-8]] is administered to the organism in an effective dose in a suitable dosage form in a suitable way selected from the group: perorally, sublingually, intranasally, rectally, vaginally, parenterally, subconjunctivally or in a chewable form.